A Non-intervention Fiberoptic Bronchoscopy Study of Remazolam Toluene Sulfonate for Injection Under General Anesthesia and Fiberoptic Bronchoscopy

Hengrui Medicine

Status: Completed

Conditions: General Anesthesia and Bronchoscopy Sedation

Treatments: Drug: Remimazolam Tosilate for Injection

Study type: Observational

Funder types: Industry

Identifiers

NCT05549791

ARMS-

Details and patient eligibility

About

This is a non-interventional study of remazolam toluenesulfonate (rebenin ®) for injection in Chinese patients. A total of 1000 patients were enrolled in this study based on the preliminary safety assessment of rebenin ®, and all safety information was obtained

Enrollment: 1,285 patients

Sex: All

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Patients using rebinim ® during general anesthesia and fiberoptic sedation
2. Patients need to sign informed consent

Exclusion criteria

1. Patients who are participating in or planning to participate in any interventional clinical trial
2. The investigator considers that there are any other reasons for the patient's ineligibility for the study

Trial design

1,285 participants in 2 patient groups

General anesthesia cohort

Treatment:

Drug: Remimazolam Tosilate for Injection

Bronchoscopy sedation cohort

Treatment:

Drug: Remimazolam Tosilate for Injection